pentobarbital will decrease the level or outcome of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will decrease the level or result of aripiprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
pentobarbital will decrease the extent or influence of fosaprepitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will decrease the extent or effect of gefitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or outcome of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to some decrease in fentanyl plasma concentrations, not enough efficacy or, perhaps, progress of a withdrawal syndrome within a individual who may have formulated Bodily dependence to fentanyl.
pentobarbital will decrease the extent or result of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.
pentobarbital will lower the extent or impact of abemaciclib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration of abemaciclib with robust CYP3A4 inducers minimizes plasma concentration of abemaciclib and its metabolites.
In accordance with a December 2020 ProPublica short what kind of drug is nembutal article, by 2017 the federal Bureau of Prisons (BOP), in discussion with then Lawyer General Jeff Sessions, experienced started to find suppliers of pentobarbital to be used in lethal injections. The BOP was aware that using pentobarbital as their "new drug decision" might be challenged within the courts due to the fact some legal professionals experienced explained that "pentobarbital would flood prisoners' lungs with froth and foam, inflicting discomfort and terror akin to some Loss of life by drowning.
Contraindicated (1)pentobarbital will lessen the level or impact of lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers can result in reduced serum concentrations and loss of antimalarial efficacy
pentobarbital will lower the extent or effect of ramelteon by impacting hepatic enzyme CYP2C9/ten metabolism. Minimal/Significance Mysterious.
Contraindicated (1)pentobarbital will decrease the level or impact of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a sensitive CYP3A4 substrate. Coadministration with powerful or average CYP3A4 inducers is contraindicated.
pentobarbital will decrease the extent or effect of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not advisable; robust cytochrome P450 enzyme inducers reduce systemic exposure to roflumilast and could decrease the therapeutic efficiency
Contraindicated (one)pentobarbital will lower the extent or influence of lorlatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the level or result of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.